ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open.
Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10186495/fb9ad32c9b
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
The conference call will also be available through live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=MezI6DhP and is also available through the company’s website.
A webcast replay of the call will be available approximately one hour after the end of the call through June 7, 2024. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (toll) or via an international dial-in number at: https://services.choruscall.com/ccforms/replay.html. Please use the following replay code 3648198. The telephonic replay will be available until March 21, 2024.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 This email address is being protected from spambots. You need JavaScript enabled to view it. | For investor inquiries: Scott Gordon for Alimera Sciences This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$5.54 |
Daily Volume: | 0 |
Market Cap: | US$301.270M |
August 06, 2024 May 14, 2024 March 19, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB